drugset / Trial / NCT01757262

A Clinical Study of Safety and P2Y12 Receptor Inhibition Effects of Ticagrelor and Clopidogrel in Vietnamese Patient

NCT01757262

Phase 3 Withdrawn AstraZeneca
RandomizedSingle-groupOpen-labelBasic science

Summary

Study in Vietnamese Patients with Coronary Heart Disease to investigate safety and P2Y12 Receptor Inhibition Effects of Ticagrelor and Clopidogrel

Timeline

Start
2013-01
Primary completion
2013-04
Completion
2013-04

Drugs

EvaluationDrugModalityDoseRoute
Comparator Clopidogrel Small molecule 75 mg
Subject Ticagrelor Small molecule 90 mg